Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families (vol 17, 61, 2022)ORPHANET JOURNAL OF RARE DISEASESIF3.52022-05-181OAAI
A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe HypoglycemiaDIABETES TECHNOLOGY & THERAPEUTICSIF6.32022-04-018OAAI
Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and familiesORPHANET JOURNAL OF RARE DISEASESIF3.52022-02-1928OAAI
PREDICTORS OF GLYCEMIC CONTROL AND DIABETES-RELATED COSTS AMONG ADULT TYPE 2 DIABETES PATIENTS INITIATING THERAPY WITH LIRAGLUTIDEVALUE IN HEALTHIF62015-05-010OAAI
Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort StudyADVANCES IN THERAPYIF42015-04-0287OAAI
Clinical Effectiveness of Liraglutide Across Body Mass Index in Patients with Type 2 Diabetes in the United States: A Retrospective Cohort StudyADVANCES IN THERAPYIF42014-09-2331OAAI
The association of body mass index with the risk of type 2 diabetes: a case-control study nested in an electronic health records system in the United StatesDIABETOLOGY & METABOLIC SYNDROMEIF3.92014-04-03188OAAI
Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label studyDIABETIC MEDICINEIF3.42011-05-1630OAAI
Examining the ability to detect change using the TRIM-Diabetes and TRIM-Diabetes Device measuresQUALITY OF LIFE RESEARCHIF2.72011-03-1920OAAI
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metforminDIABETIC MEDICINEIF3.42011-02-1054PREAI
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetesDIABETES OBESITY & METABOLISMIF5.72010-05-2859OAAI
Development and validation of the Treatment Related Impact Measure of Weight (TRIM-Weight)HEALTH AND QUALITY OF LIFE OUTCOMESIF3.42010-01-0113OAAI
Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device)HEALTH AND QUALITY OF LIFE OUTCOMESIF3.42009-09-0962OAAI
VALIDATION OF THE TREATMENT RELATED IMPACT MEASURE FOR DIABETES TREATMENT AND DEVICE; TRIM-DIABETES AND TRIM-DIABETES DEVICEVALUE IN HEALTHIF62009-05-010OAAI
PATIENT REPORTED OUTCOMES ARE SUPERIOR IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH LIRAGLUTIDE AS COMPARED TO EXENATIDE, WHEN ADDED TO METFORMIN, SULFONYLUREA OR BOTHVALUE IN HEALTHIF62009-05-010OAAI
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazoneCARDIOVASCULAR DIABETOLOGYIF10.62009-01-0124OAAI
UNDERSTANDING AND ASSESSING THE IMPACT OF PRESCRIPTION WEIGHT LOSS MEDICATION; CONCEPTUAL, GENDER AND CULTURAL ISSUESVALUE IN HEALTHIF62008-11-011OAAI
Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutideDIABETES OBESITY & METABOLISMIF5.72008-06-2821PREAI
A case of sequential anti-stress medication in a patient with major depression resistant to amine-reuptake inhibitorsActa Psychiatrica ScandinavicaIF52007-11-136PREAI
Health related quality of life on body mass index for people with type 2 diabetes in the general adult population in EnglandVALUE IN HEALTHIF62007-05-010OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向